Record mula sa primary source
Decision-gradeTopline na resulta
Merck/Eisai: hindi naabot ng triplet regimens ng LITESPARK-012 ang PFS/OS endpoints kumpara sa KEYTRUDA+LENVIMA
Ipinakita ng Phase 3 LITESPARK-012 trial na ang pagdaragdag ng belzutifan o quavonlimab sa KEYTRUDA plus LENVIMA ay hindi nagpabuti ng PFS o OS kumpara sa aprubadong KEYTRUDA plus LENVIMA doublet sa first-line advanced clear cell RCC. Nanatiling pare-pareho ang mga safety profile sa mga naunang pag-aaral. Ang negatibong resulta ay hindi nakakaapekto sa iba pang kasalukuyang LITESPARK trials o sa Oct 4 2026 PDUFA para sa LITESPARK-011 sNDA.
Mahahalagang fact
- Na-file
- Abr 21, 2026, 10:45 AM
- Kaganapan
- Topline na resulta
- Direksyon
- Negatibo
- Kumpanya
MRKMSD- Asset
- belzutifan
- Pinagmulan
- Press release ng kumpanya
- Kumpiyansa
- May source
Sipi mula sa source
Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC) Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC) Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC) Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced results from the Phase 3 LITESPARK-012 trial evaluating combination regimens for the first-line treatment of patients with advanced clear cell renal cell carcinoma (RCC). The trial evaluated